| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of 105.000 patients with cancer: have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands
|
Walraven, J.E.W.
|
|
|
121 |
C |
p. 85-93
|
artikel
|
| 2 |
Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer
|
Belderbos, Bodine P.S.
|
|
|
121 |
C |
p. 48-54
|
artikel
|
| 3 |
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations
|
George, Sally L.
|
|
|
121 |
C |
p. 224-235
|
artikel
|
| 4 |
BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports
|
Melin, Audrey
|
|
|
121 |
C |
p. 109-112
|
artikel
|
| 5 |
Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition
|
Tonk, Erwin H.J.
|
|
|
121 |
C |
p. 1-3
|
artikel
|
| 6 |
Clinical features of neuroendocrine prostate cancer
|
Conteduca, Vincenza
|
|
|
121 |
C |
p. 7-18
|
artikel
|
| 7 |
Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting
|
Liang, Fei
|
|
|
121 |
C |
p. 19-28
|
artikel
|
| 8 |
Current state of quality of life and patient-reported outcomes research
|
Bottomley, Andrew
|
|
|
121 |
C |
p. 55-63
|
artikel
|
| 9 |
Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia
|
Choi, Min Chul
|
|
|
121 |
C |
p. 94-97
|
artikel
|
| 10 |
Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial
|
Doi, Toshihiko
|
|
|
121 |
C |
p. 29-39
|
artikel
|
| 11 |
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
|
Moreira, A.
|
|
|
121 |
C |
p. 202-209
|
artikel
|
| 12 |
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
|
Jiang, Tao
|
|
|
121 |
C |
p. 98-108
|
artikel
|
| 13 |
Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab
|
Song, Peng
|
|
|
121 |
C |
p. 4-6
|
artikel
|
| 14 |
Finnish sauna bathing does not increase or decrease the risk of cancer in men: A prospective cohort study
|
Laukkanen, Jari A.
|
|
|
121 |
C |
p. 184-191
|
artikel
|
| 15 |
Immune gene expression in head and neck squamous cell carcinoma patients
|
Lecerf, Charlotte
|
|
|
121 |
C |
p. 210-223
|
artikel
|
| 16 |
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials
|
Davidson, Michael
|
|
|
121 |
C |
p. 40-47
|
artikel
|
| 17 |
Measured and genetically predicted plasma YKL-40 levels and melanoma mortality
|
Ismail, Hafsa
|
|
|
121 |
C |
p. 74-84
|
artikel
|
| 18 |
Metabolic crosstalk in the breast cancer microenvironment
|
Dias, Ana S.
|
|
|
121 |
C |
p. 154-171
|
artikel
|
| 19 |
Nivolumab-related mucous membrane pemphigoid
|
Sibaud, Vincent
|
|
|
121 |
C |
p. 172-176
|
artikel
|
| 20 |
Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting
|
Corbaux, Pauline
|
|
|
121 |
C |
p. 192-201
|
artikel
|
| 21 |
Pemetrexed exposure predicts toxicity in advanced non–small-cell lung cancer: A prospective cohort study
|
Visser, S.
|
|
|
121 |
C |
p. 64-73
|
artikel
|
| 22 |
Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
|
Kopp, Lisa M.
|
|
|
121 |
C |
p. 177-183
|
artikel
|
| 23 |
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
|
Rivin del Campo, Eleonor
|
|
|
121 |
C |
p. 130-143
|
artikel
|
| 24 |
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
|
Saleh, Khalil
|
|
|
121 |
C |
p. 123-129
|
artikel
|
| 25 |
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
|
Schadendorf, Dirk
|
|
|
121 |
C |
p. 144-153
|
artikel
|
| 26 |
Treatment-related mortality in children with cancer: Prevalence and risk factors
|
Loeffen, Erik A.H.
|
|
|
121 |
C |
p. 113-122
|
artikel
|
Tijdschrift beschrijving